M
Michael Mengel
Researcher at University of Alberta
Publications - 263
Citations - 21923
Michael Mengel is an academic researcher from University of Alberta. The author has contributed to research in topics: Transplantation & Kidney. The author has an hindex of 69, co-authored 248 publications receiving 19023 citations. Previous affiliations of Michael Mengel include Harvard University & Hochschule Hannover.
Papers
More filters
Journal ArticleDOI
Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions
Kim Solez,Robert B. Colvin,Lorraine C. Racusen,Mark Haas,Banu Sis,Michael Mengel,Philip F. Halloran,William M. Baldwin,G. Banfi,A. B. Collins,Fernando G. Cosio,D. S. R. David,Cinthia B. Drachenberg,Gunilla Einecke,Agnes B. Fogo,Ian W. Gibson,Denis Glotz,Samy S. Iskandar,Edward S. Kraus,Evelyne Lerut,Roslyn B. Mannon,Michael J. Mihatsch,Brian J. Nankivell,Volker Nickeleit,John C. Papadimitriou,Parmjeet Randhawa,Heinz Regele,Karine Renaudin,Ian S.D. Roberts,Daniel Serón,Rex Neal Smith,Marialuisa Valente +31 more
TL;DR: Emerging research data led to the establishment of collaborative working groups addressing issues like isolated ‘v’ lesion and incorporation of omics‐technologies, paving the way for future combination of graft biopsy and molecular parameters within the Banff process.
Journal ArticleDOI
Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence.
Joana Sellarés,D. G. de Freitas,Michael Mengel,Jeff Reeve,Gunilla Einecke,Banu Sis,Luis G. Hidalgo,Konrad S. Famulski,Arthur J. Matas,Philip F. Halloran +9 more
TL;DR: This prospective cohort indicates that many actual failures after indication biopsies manifest phenotypic features of antibody‐mediated or mixed rejection and also underscores the major role of nonadherence.
Journal ArticleDOI
Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions
Mark Haas,Banu Sis,Lorraine C. Racusen,Kim Solez,Denis Glotz,Robert B. Colvin,Maria Castro,D. S. R. David,Elias David-Neto,Serena M. Bagnasco,Linda C. Cendales,Lynn D. Cornell,Anthony J. Demetris,Cinthia B. Drachenberg,Carol Farver,Alton B. Farris,Ian W. Gibson,Edward S. Kraus,Helen Liapis,Alexandre Loupy,Volker Nickeleit,Parmjeet Randhawa,E. R. Rodriguez,David N. Rush,Rex Neal Smith,Carmela D. Tan,William D. Wallace,Michael Mengel +27 more
TL;DR: The 12th Banff Conference on Allograft Pathology was held in Comandatuba, Brazil, from August 19-23, 2013, and was preceded by a 2-day Latin American Symposium on Transplant Immunobiology and Immunopathology.
Journal ArticleDOI
Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN').
Kim Solez,Robert B. Colvin,Lorraine C. Racusen,Banu Sis,Philip F. Halloran,Patricia E. Birk,Patricia Campbell,Marilia Cascalho,A. B. Collins,Anthony J. Demetris,Cinthia B. Drachenberg,Ian W. Gibson,Paul C. Grimm,Mark Haas,Evelyne Lerut,Helen Liapis,Roslyn B. Mannon,P. B. Marcus,Michael Mengel,Michael J. Mihatsch,Brian J. Nankivell,Volker Nickeleit,John C. Papadimitriou,Jeffrey L. Platt,Parmjeet Randhawa,Ian Roberts,L. Salinas-Madriga,Daniel R. Salomon,Daniel Serón,M. Sheaff,Jan J. Weening +30 more
TL;DR: The 8th Banff Conference on Allograft Pathology was held in Edmonton, Canada, 15–21 July 2005, and major outcomes included the elimination of the non‐specific term ‘chronic allograft nephropathy’ (CAN) and the recognition of the entity of chronic antibody‐mediated rejection.
Journal ArticleDOI
The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials
Mark Haas,Alexandre Loupy,Carmen Lefaucheur,Candice Roufosse,Denis Glotz,Daniel Serón,Brian J. Nankivell,Philip F. Halloran,Robert B. Colvin,Enver Akalin,Nada Alachkar,Serena M. Bagnasco,Yassine Bouatou,Yassine Bouatou,Jan U. Becker,Lynn D. Cornell,J.-P. Duong Van Huyen,Ian W. Gibson,Edward S. Kraus,Roslyn B. Mannon,Maarten Naesens,Volker Nickeleit,Peter Nickerson,Dorry L. Segev,Harsharan K. Singh,Mark D. Stegall,P. Randhawa,Lorraine C. Racusen,Kim Solez,Michael Mengel +29 more
TL;DR: The Banff ABMR criteria are updated and paves the way for the Banff scheme to be part of an integrative approach for defining surrogate endpoints in next‐generation clinical trials.